

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Organizing Chairperson

Dr. B. K. Smruti
Dr. Mehul Bhansali
Dr. Kumar Prabhash

Organizing Secretaries

Dr. Vijay Patil
Dr. Rakesh Katna
Dr. Sarbani Laskar

Jt. Organizing Secretaries

Dr. Shivkumar Thiagarajan
Dr. Ashay Karpe
Dr. Trinanjan Basu

Scientific Committee Chair

Dr. Vanita Noronha

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by
riverroute[®]

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Dear Colleagues,

We are honored to extend a warm invitation to you for the **"7th Annual International Conference in Head & Neck Cancer"**, scheduled to take place on the **28th and 29th of September, 2024**, at the **Royal Palace, NSCI, Worli, Mumbai**. This meeting is hosted by Mumbai Oncology Association and supported by Indian Society of Paediatric and Medical Oncology and Cancer Research and Statistic Trust.

This conference promises to be a remarkable event, bringing together leading experts, researchers, and clinicians in the field of head and neck cancer. Over the course of two days, we will delve into **the most significant and cutting-edge publications and abstracts, carefully selected from national and international journals and conferences.**

The top 80 publications, chosen for their innovative contributions and clinical relevance, will be presented in a structured and detailed manner, categorized by site-specific and treatment-specific themes. **Each oral presentation will be followed by an engaging panel discussion, allowing for an in-depth exploration of the applicability of these findings in clinical practice.**

Your presence and participation would be invaluable to the success of this event. We are confident that your insights and expertise will greatly enrich the discussions and contribute to the advancement of our collective knowledge and practice in this crucial field.

We look forward to welcoming you to Mumbai and to what promises to be an inspiring and intellectually stimulating conference.

Warm regards,

Dr. B. K. Smruti
Dr. Mehul Bhansali
Dr. Kumar Prabhash

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Committee

Dr. Sewanti Limaye
Dr. Nandini Menon
Dr. Minit Shah
Dr. Manjusha Vagal
Dr. Poonam Joshi
Dr. Arjun Singh
Dr. Shivshankar Timmanpyati
Dr. Karan Gupta
Dr. Rushabh Kothari
Dr. Prahlad Yathiraj
Dr. Shwetabh Sinha
Dr. Deepak Balasubramaniam
Dr. Monali Swain
Dr. Goutam Panda
Dr. Rakesh Pinniti
Dr. Bhuvan Chugh
Dr. Dushyant Mandlik
Dr. Neha Mittal
Dr. Krishnakumar Thankappan
Dr. Anuradha Daptardar
Dr. Anshul Singla
Dr. Deepanjali Adulkar
Dr. Kinjal Jani

Dr. Rohit Pai
Dr. Mansi Khanderia
Dr. Sunil Chopade
Dr. Anuj Kumar
Dr. Rakesh Katna
Dr. Abhishek Mahajan
Dr. Mandar Deshpande
Dr. Arun Balaji
Dr. Akhil Kapoor
Dr. Kaustav Talapatra
Dr. Nikhil Kalyani
Dr. Nikhilesh Borkar
Dr. Shilpi Sharma
Dr. Suyash Kulkarni
Dr. Mukul Roy
Dr. Vaibhav Chaudhary
Dr. Kunal Jobunputra
Dr. Anabarsan Sekar
Dr. Deep Vora
Dr. Aman Sharma
Dr. Shrinivas Kulkarni
Dr. Kshitij Domadia
Dr. Gaurav Prakash

Session Coordinators:

Dr. Laboni Sarkar
Dr. Devanshee Shah
Dr. Ramjas Prajapati

Dr. Harsh Sahu
Dr. Deep Vora
Dr. Laxma Reddy

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

09:00am - 01:00pm	Session Coordinators: Dr. Laboni Sarkar, Dr. Devanshee Shah
	SESSION 1: Key abstracts to be presented on cancers of oral cavity
	CHAIRPERSONS: Dr. Vivek Anand, Dr. Mehul Bhansali
09:00am - 09:10am	Reviewer: Dr. Shivakumar Thiagarajan Transoral robotic surgery without adjuvant therapy: A systematic review and meta-analysis of the association between surgical margins and local recurrence. Author: Andrew Williamson Citation: Oral Oncol. 2023 Dec:147:106610 <hr/> Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients and implications for clinical practice. Author: Vanita Noronha Citation: 2024 Jan:148:106633
09:10am - 09:20am	Reviewer: Dr. Prahlad Yathiraj Adjuvant radiotherapy mitigates impact of perineural invasion on oncologic outcomes in early-stage oral cavity squamous cell carcinoma. A multi-institutional analysis of 557 patients Author: Andrew J Holcomb Citation: Oral Oncol. 2023 Jul:142:106420 <hr/> The impact of multifocal perineural invasion in predicting survival in patients with oral squamous cell carcinoma: A multicenter investigation Author: Shaheen Hasmat Citation: Head Neck. 2023 Oct; 45(10):2605-2612 NOVEMBER 01, 2022

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

09:20am - 09:30am	<p>Reviewer: Dr. Anshul Singla</p> <p>Health-related quality of life, functional outcomes, and complications after sentinel lymph node biopsy and elective neck dissection in early oral cancer: A systematic review Author: Christopher McDonald MFDS, FRCS Citation: Head Neck. 2023 Nov;45(11):2754-2779</p>
	<p>Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity. Author: Sarbani G. Laskar Citation: EJC ORIGINAL RESEARCH VOLUME 181, P179-187, MARCH 2023</p>
	<p>CHAIRPERSONS: Dr. Vijay Haribhakti, Dr. Shyam Shrivastava</p>
09:30am - 10:00am	<p>Panel discussion on presented key abstracts of cancers of oral cavity</p> <p>MODERATOR: Dr. Vikram Kekatpure</p> <p>PANELISTS: Dr. Yusuf Mistry, Dr. Nikhilesh Borkar, Dr. Ashwini Budrukkar, Dr. Salil Patkar, Dr. Suparna Rao, Dr. Anuj Kumar PG, Dr. Prahalad Yathiraj</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

SESSION 2: Key abstracts to be presented on Oropharyngeal Cancer

CHAIRPERSONS: Dr. Sharmila Agarwal, Dr. Girish Phadke

10:00am - 10:10am

Reviewer: Dr. Trinanjan Basu

Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC)

Author: Steven J. Frank, MD

Citation: ASCO Abstract: 6006

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial

Author: Christopher Nutting

Citation: Lancet Oncol., 2023 Aug;24(8):868-880

10:10am - 10:20am

Reviewer: Dr. Arjun Singh

Differences in Functional and Survival Outcomes Between Patients Receiving Primary Surgery vs Chemoradiation Therapy for Treatment of T1-T2 Oropharyngeal Squamous Cell Carcinoma

Author: Dev R Amin

Citation: JAMA Otolaryngol Head Neck Surg., 2023 Nov 1;149(11):980-986

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

	<p>Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation Author: Alisha R. Pershad Citation: Cancer Med. 2024 Apr; 13(7): e7146</p>
10:20am - 10:30am	<p>Reviewer: Dr. Arnav Tongaonkar</p> <p>Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial Author: Ari J Rosenberg Citation: JAMA Oncol. 2024 Jul 1;10(7):923-931</p> <p>Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV Author: Ari Joseph Rosenberg, MD Citation: ASCO Abstract: 6017</p>
10:30am - 10:40am	<p>Reviewer: Dr. Ashwini Budrukkar</p> <p>Intensity-Modulated Radiation Therapy Alone Versus Intensity-Modulated Radiation Therapy and Brachytherapy for Early-Stage Oropharyngeal Cancers: Results From a Randomized Controlled Trial Author: Ashwini Budrukkar Citation: Int J Radiat Oncol Biol Phys. 2024; 118:5: 1541-1551</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by
riverroute

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

	CHAIRPERSONS: Dr. Sumit Basu, Dr. Shishir Shetty
10:40am - 11:10am	Panel Discussion on presented key abstracts of Oropharyngeal Cancers
	MODERATORS: Dr. Kaustav Talapatra, Dr. Adwaita Gore PANELISTS: Dr. Sarbani Laskar, Dr. Trinanjan Basu, Dr. Lovin Wilson, Dr. Devendra Chaukar, Dr. Sudhir Nair, Dr. Vinay Babu, Dr. Mandar Deshpande, Dr. Avinash Talele
11:10am - 11:20am	Tea/Coffee Break
Session 3: Key abstracts to be presented on Nasopharyngeal Cancer	
	CHAIRPERSONS: Dr. Vikram Kekatpure, Dr. Nikhilesh Borkar
11:20am - 11:30am	Reviewer: Dr. Harsh Sahu
	Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial Author: Min Kang Citation: ASCO Abstract: 6002
	Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial Author: Chaosu Hu (Shanghai, China) Citation: ASCO 2024 Abstract 6075

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

11:30am - 11:40am	<p>Reviewer: Dr. Aman Sharma</p> <p>Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: A multicentre, randomised, open-label, phase 3 trial Author: Rui You Citation: Lancet 2023 Mar 18;401(10380):917-927</p>
	<p>Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: A meta-analysis Author: Xiaoxu Ding Citation: Radiother Oncol. 2023 Nov:188:109860</p>
11:40am - 11:50am	<p>Reviewer: Dr. Monali Swain</p> <p>The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours Author: Carlo Resteghini Citation: Eur J Cancer. 2023 Jul:187:185-194</p>
	<p>The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours Author: Paolo Bossi Citation: Eur J Cancer. 2023 Jul:187:134-143</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by



Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

11:50am - 12:00pm	<p>Reviewer: Dr. Rakesh Katna</p> <p>Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN Cancer Research Group (EA3163) Author: Nabil F. Saba (Atlanta, United States of America, GA) Citation: ESMO 2024. Abstract 850MO</p>
12:00pm - 12:10pm	<p>Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison. Author: Yibin Liu Citation: J of Otolaryngol - Head & Neck Surg 52, 72 (2023)</p> <p>Reviewer: Dr. Laboni Sarkar</p> <p>Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) Author: Wan Qin Chong (Singapore, Singapore) Citation: ESMO 2024 Abstract 848MO</p> <p>Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial Author: Xu Liu, MD Citation: ASCO Abstract: LBA6000</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by
riverroute[®]

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

	<p>Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial Author: Li-Ting Liu Citation: Lancet Oncol., 2023 Jul;24(7):798-810</p>
--	---

CHAIRPERSONS: Dr. Rakesh Katna, Dr. Chanchal Goswami

12:10pm - 12:55pm

Panel discussion on presented abstracts in Nasopharyngeal Cancer

MODERATORS: Dr. Kshitij Joshi, Dr. Sanjay M.H.

PANELISTS: Dr. Nikhil Kalyani, Dr. Bhavin Visariya, Dr. Amit Chakraborty, Dr. Vikas Talreja, Dr. Monali Swain, Dr. Rakesh Katna, Dr. Darshit Shah, Dr. Pritam Jain, Dr. Sandeep De

01:00pm - 01:45pm

Lunch

01:45pm - 06:00pm

Session Coordinators: Dr. Ramjas Prajapati, Dr. Harsh Sahu

Session 4 Key abstracts to be presented on Supportive Care in H&N Cancers

01:45pm - 01:55pm

CHAIRPERSONS: Dr. Nagraj Huilgol, Dr. Mandar Deshpande

Reviewer: Dr. Deepanjali Adulkar

Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial.

Author: Xingchen Peng.

Citation: J Clin Oncol. 2024 Apr 20;42(12):1426-1435

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

	<p>Salivary Electrostimulation in the Treatment of Radiation Therapy-Induced Xerostomia (-2): A Multicenter, Randomized, Double-Masked, Sham-Controlled, Phase 3 Trial</p> <p>Author: Int J Radiat Citation: Oncol Biol Phys</p>
01:55pm - 02:05pm	<p>Reviewer: Dr. Anuj Shah</p> <p>The efficacy of Kinesio taping on lymphedema following head and neck cancer therapy: a randomized, double blind, sham-controlled trial</p> <p>Author: Sevgi Atar Citation: Physiother Theory Pract 2023 Sep2;39(9):1832-1846</p>
	<p>Evaluation of Anterolateral Thigh Fascia Lata Rescue Flap for Mandibular Osteoradionecrosis.</p> <p>Author: Khashayar Arianpour Citation: JAMA Otolaryngol Head Neck Surg., 2023 Jul 1;149(7):621-627</p>
02:05pm - 02:15pm	<p>Reviewer: Dr. Purvi Rathod</p> <p>Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial</p> <p>Author: Joël Castelli Citation: JAMA Oncol. 2023 Aug 1;9(8):1056-1064</p>
	<p>A systematic review and meta-analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer</p> <p>Author: Kun-Wei Chiu Citation: Oral Oncol 2024 Jan;148:106649</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by
riverroute

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

02:15pm - 02:25pm	<p>Reviewer: Ms. Divyal Vira</p> <p>Nutrition and head-neck cancer: A prospective observational study in patients with head neck cancer receiving adjuvant/definitive radiotherapy/chemoradiotherapy Author: Dr. Chetan Dilip Deshmukh Citation: ASCO 2024 Abstract e18784</p>
	<p>Effects of different nutritional support methods on nutritional status and immune function in patients undergoing radiotherapy for head and neck cancer Author: Jianqi Yang Citation: Clin Transl Oncol. 2024 Aug 18</p>
02:25pm - 02:35pm	<p>Reviewer: Dr. Ajeeta Kulkarni</p> <p>Prophylactic Swallowing Therapy During Head-and-Neck Cancer Radiotherapy: Effect of Service-Delivery Mode and Overall Adherence Level on Swallowing Function and Muscle Strength-the PRESTO Trial Author: Margot Baudelet Citation: Dysphagia 2024 Apr;39(2):267-281 doi: 10.1007/s00455-023-10609-7</p>
	<p>Effect of exercise across the head and neck cancer continuum: a systematic review of randomized controlled trials Author: Alice Avancini Citation: Support Care Cancer 2023 Nov 4;31(12):670</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by
riverroute

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

02:35pm - 03:05pm

Industry Session 1 - MSD

Role of IO and it's sequencing strategy in the management of HNSCC

Speaker - Dr. Amit Bhatt

Session 5 Key abstracts to be presented on Targeted Therapy / Bio-Marker

03:05pm - 03:20pm

CHAIRPERSONS: **Dr. Shailesh Bondarde, Dr. Amrit Kaler**

Reviewer: **Dr. Bhuvan Chugh**

BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

Author: Priscilla K Brastianos

Citation: N Engl J Med. 2023 Jul 13;389(2):118-126

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

Author: Julien Hadoux

Citation: N Engl J Med. 2023 Nov 16;389(20):1851-1861

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

Author: Jessica C Hassel

Citation: N Engl J Med. 2023 Dec 14;389(24):2256-2266

A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)

Author: A. L. Ho

Citation: ESMO 2023 LBA47 Abstract | Volume 34, Supplement 2, S1286-S1287, October 2023

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

03:20pm - 03:35pm

Reviewer: Dr. Neha Mittal

Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor

Author: Natasha Honore

Citation: Eur J Cancer. 2023 Dec;195:113372

Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial

Author: Bhumsuk Keam

Citation: J Clin Oncol. 2024 Feb 10;42(5):507-517

Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck

Author: N Honore

Citation: Ann Oncol.,2023 Dec;34(12):1175-1186

03:35pm - 04:15pm

CHAIRPERSONS: Dr. Kumar Prabhash, Dr. Rajat Saha

Panel discussion on Precision Oncology and biomarkers in Head and Neck Cancers

MODERATOR: Dr. B. K. Smruti

PANELISTS: Dr. Kiran Tamkhane, Dr. Vanita Noronha, Dr. Omshree Shetty, Dr. Jay Mehta, Dr. Vijay Sharnagat, Dr. Bhuvan Chugh

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

Session 6 Key abstracts to be presented on Targeted Thyroid/Salivary Gland

04:15pm - 04:25pm

CHAIRPERSONS: Dr. Sudesh Phanse, Dr. Sandeep De, Dr. Suvarna Achrekar

Reviewer: Dr. Anuj Kumar

Oncologic Safety of Close Margins in Patients With Low-to Intermediate-Grade Major Salivary Gland Carcinoma.

Author: Mirabelle Sajisevi

Citation: JAMA Otolaryngol Head Neck Surg., 2024 Feb 1;150(2):107-116

Long-Term Outcomes and Risk Factors of Radiofrequency Ablation for T1N0M0 Papillary Thyroid Carcinoma

Author: Xinyang Li

Citation: JAMA Surg 2024 Jan 1;159(1):51-58

04:25pm - 04:35pm

Reviewer: Dr. Ekta Vala

Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: results from the MYTHOS trial

Author: Ichiro Kinoshita (Sapporo, Japan)

Citation: ESMO 2024. Abstract 8490

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial

Author: Eric J Sherman

Citation: Lancet Oncol 2023 Feb;24(2):175-186

04:35pm - 04:45pm

Reviewer: Dr. Devanshee Shah

Neoadjuvant tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a single centre case series

Author: J J Y Yeo

Citation: J Laryngol Otol., 2023 Nov;137(11):1237-1243

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

	<p>Carcinomas of the external auditory canal: Management and results: A multicenter REFCOR propensity score matching study Author: Esteban Brenet Citation: Eur J Cancer. 2024 Apr;201:113922</p>
04:45pm - 05:15pm	<p>Panel discussion presented publications of Thyroid / Salivary Gland</p>
	<p>MODERATOR: Dr. Nandini Menon PANELISTS: Dr. Rajat Saha, Dr. Goutam Panda, Dr. Shivam Shingla, Dr. Anuj Kumar, Dr. Kajari Bhattacharya</p>
05:15pm - 05:30pm	<p>Hi-Tea Session</p>
05:30pm - 06:00pm	<p>Industry Session 2 - Alkem</p>
	<p>CHAIRPERSON: Dr. S. H. Advani</p>
05:30pm - 05:40pm	<p>Addressing Advanced Oral Cancers in India with targeted chemotherapy Speaker - Dr. Nandini Menon</p>
05:40pm - 06:00pm	<p>Case Based Panel Discussion: Sequencing Cetuximab with Immunotherapy: Response Rates in Bulky Tumors</p>
	<p>MODERATOR: Dr. Akhil Kapoor PANELISTS: Dr. Shivam Shingla, Dr. Darshit Shah, Dr. Vijay Sharnagat, Dr. Srinivas Kulkarni</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

28th September, 2024 — Day 1

06:00pm - 06:15pm

Industry Session 3 - ThermoFisher

06:00pm - 06:15pm

Optimizing Cancer Research workflows with OncoPrint
Speaker - Mr. Pravin Nilawe

06:15pm - 07:15pm

Students Quiz

Quiz Master - Dr. Sunil Chopade, Dr. Kunal Jobanputra

08:00pm Onwards

Dinner

Click on the link below for registration
<https://riveroute.in/arhnc2024>

Managed by

riveroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

29th September, 2024 — Day 2

09:00am - 01:00pm	<p>Session Coordinators: Dr. Deep Vora, Dr. Laxma Reddy</p> <p>Session 7 Key abstracts to be presented on LA - HNSCC</p>
09:00am - 09:15am	<p>CHAIRPERSONS: Dr. Sanjay Dudhat, Dr. Vikram Sanghvi</p> <p>Reviewer: Dr. Deep Vora</p> <p>MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)ESMO 2023 Abstract 8570 Author: P. Blanchard Citation: ABSTRACT VOLUME 34, SUPPLEMENT 2, S556, OCTOBER 2023</p> <p>Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck Author: Vijay Maruti Patil Citation: ASCO Abstract LBA6092</p>
09:15am - 09:25am	<p>Reviewer: Dr. Sunil Chopade</p> <p>Neoadjuvant chemotherapy for locally advanced head and neck squamous cell carcinoma - Is it still relevant? A practice pattern survey among oncologists of India Author: Anis Bandyopadhyay Citation: J Cancer Res Ther. 2023 Jul-Sep;19(5):1316-1323</p> <p>Neoadjuvant-adjuvant pembrolizumab in resectable advanced basal cell carcinoma of the head and neck: An open-label, single-arm, phase 1b trial Author: Grace M. Jones Citation: AACR Abstract 7518:Proffered paper. Cancer Res (2024) 84(6_Supplement): 7518</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

29th September, 2024 — Day 2

09:25am - 09:35am

Reviewer: Dr. Ramjas Prajapati

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Author: Jean-Pascal Machiels

Citation: Lancet Oncol., 2024 May;25(5):572-587

A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation

Author: Alexander Rühle

Citation: Int J Radiat Oncol Biol Phys 2024 Apr 1;118(5):1282-1293

09:35am - 09:45am

Reviewer: Dr. Mukul Roy

Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma.

Author: Chia-Lun Chang.

Citation: Radiotherapy and Oncology 190:109971.

Acute Toxicity Results from the Randomized Assessment of Cisplatin Dosing Interval for Ototoxicity (RADIO) Trial Comparing Chemoradiation (CRT) with Cisplatin Q3weekly to Weekly for Locally Advanced Squamous Cell Carcinoma of the Head and neck (LASCCHN).

Author: Int J Radiat.

Citation: Oncol Biol Phys.

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

29th September, 2024 — Day 2

09:45am - 09:55am	<p>Reviewer: Dr. Richa Vaish</p> <p>Diagnostic accuracy of intraoperative margin assessment techniques in surgery for head and neck squamous cell carcinoma: A meta-analysis. Author: James A Higginson. Citation: Oral Oncol. 2023 Jul;142:106419.</p> <p>Prognostic Value of Radiological Extranodal Extension Detected by Computed Tomography for Predicting Outcomes in Patients With Locally Advanced Head and Neck Squamous Cell Cancer Treated With Radical Concurrent Chemoradiotherapy. Author: Abhishek Mahajan. Citation: Front Oncol. 2022 May 27;12:814895.</p>
09:55am - 10:25am	<p>Industry Session 4 - ERIS Life Sciences</p> <p>LBA6092- Long term results of a randomized phase III study of Nimotuzumab with concurrent chemoradiation versus chemoradiation alone in locally advanced squamous cell carcinoma of head and neck Speaker - Dr. Nandini Menon</p>
10:25am - 11:10am	<p>CHAIRPERSONS: Dr. Sudeep Sarkar, Dr. Dilip Nikam</p> <p>Panel discussion presented publications of LA HNSCC</p>
11:10am - 11:20am	<p>MODERATOR: Dr. Vijay Patil</p> <p>PANELISTS: Dr. Mukul Roy, Dr. Rohit Malde, Dr. Yashwant Kashyap, Dr. Shriniwas Kulkarni, Dr. Ravikant Singh, Dr. Alok Goel</p>
11:10am - 11:20am	Tea/Coffee Break

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

29th September, 2024 — Day 2

11:20am - 11:35am

Industry Session 5 - Dr. Reddy's Laboratories Ltd.

Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)

Speaker - Dr. Akhil Kapoor

Session 8 Key abstracts to be presented on R/M - HNSCC

CHAIRPERSONS: Dr. Devendra Pal, Dr. Ranjeet Bajpai

11:35am - 11:45am

Reviewer: Dr. Akhil Kapoor

Long term results of phase 3 randomized study evaluating the addition of low dose nivolumab to palliative chemotherapy in head and neck cancer.

Author: Vijay Maruti Patil.

Citation: ASCO Abstract LBA6054.

Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status.

Author: Vijay Maruti Patil.

Citation: ASCO Abstract: LBA6019.

11:45am - 11:55am

Reviewer: Dr. Kshitij Domadia

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck. Hideki Tanaka., Front. Oncol.

Author: Hideki Tanaka.

Citation: Front. Oncol., 21 November 2023, Sec. Head and Neck Cancer Volume 13 - 2023.

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

29th September, 2024 — Day 2

	<p>Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer HNSCC).</p> <p>Author: M. Bonomi.</p> <p>Citation: ESMO 2023 930P VOLUME 34, SUPPLEMENT 2, S586, OCTOBER 2023.</p>
11:55am - 12:05pm	<p>Reviewer: Dr. Vijai Simha</p> <p>Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial. ESMO 2023 859MO</p> <p>Author: L. Michel.</p> <p>Citation: ABSTRACT VOLUME 34, SUPPLEMENT 2, S558, OCTOBER 2023.</p>
	<p>REWRITE-GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck.</p> <p>Author: Joël Castelli (Rennes, France).</p> <p>Citation: ESMO 2024 852MO.</p>
12:05pm - 12:20pm	<p>Reviewer: Dr. Alok Goel</p> <p>A phase IV study of EXTREME regimen versus nivolumab plus paclitaxel and cisplatin/carboplatin-based regimen in recurrent or metastatic squamous cell carcinoma of the head and neck.</p> <p>Author: A.D. Khadela.</p> <p>Citation: ABSTRACT VOLUME 9, SUPPLEMENT 1, 102361, FEBRUARY 2024.</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Scientific Program

29th September, 2024 — Day 2

	<p>Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial. Author: Nabil F Saba. Citation: JAMA Oncol. 2024 Jul 1;10(7):896-904.</p> <p>Nivolumab for Patients With High-Risk Oral Leukoplakia: A Non-randomized Controlled Trial Author: Glenn J Hanna. Citation: JAMA Oncol. 2024 Jan 1;10(1):32-41.</p>
12:20pm - 01:05pm	<p>CHAIRPERSONS: Dr. S. H. Advani, Dr. Reetu Jain</p> <p>Cellular Therapies Update Speaker - Dr. Vijay Patil</p>
01:05pm - 01:45pm	<p>Panel discussion presented publications of R/M HNSCC</p> <p>MODERATOR: Dr. Vanita Noronha</p> <p>PANELISTS: Dr. Mubarakunnisa Tonse, Dr. Uma Dangi, Dr. Siddharth Turkar, Dr. Arun Chandrasekharan, Dr. Ashay Karpe, Dr. Gunjesh Singh, Dr. Bhavesh Poladia, Dr. Annu Rajpurohit</p>
01:45pm - 01:50pm	<p>Vote of Thanks</p>
01:50pm Onwards	<p>Lunch and Departure</p>

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute®

Organized by



Supported by



7th Annual International Review in Head & Neck Cancers



28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Academic Partners



Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by
riverroute



Images only for representative purpose.

A KEY TO MORE POSSIBILITIES

for your
HNSCC patients



For 1st Line R/M HNSCC

KEYTRUDA® (pembrolizumab) in combination with platinum and 5-FU, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.

KEYTRUDA® (pembrolizumab) as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [CPS ≥1].

HNSCC: head and neck squamous cell carcinoma; **5-FU:** 5-fluorouracil; **CPS:** Combined Positive Score; **PD-L1:** Programmed death-ligand 1

Reference: KEYTRUDA® (pembrolizumab) Prescribing Information MSDIN 06/23

For complete Prescribing Information
please scan the QR code below



Selected Safety Information (SSI):

None | **Warnings and Precautions:** Immune-mediated adverse reactions, including severe and fatal cases have occurred in patients receiving KEYTRUDA. Immune-mediated adverse reactions can occur after discontinuation of treatment. In clinical trials, most immune-mediated adverse reactions were reversible and managed with interruptions of KEYTRUDA®, administration of corticosteroids and/or supportive care. Immune-mediated pneumonitis, Immune-mediated colitis, Immune-mediated hepatitis, Immune-mediated nephritis, Immune-mediated endocrinopathies (as adrenal insufficiency, hypophysitis, hypophysitis (including hypopituitarism), type 1 diabetes mellitus (including diabetic ketoacidosis), hyperthyroidism, hypothyroidism and thyroiditis), Severe skin reactions, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), uveitis, myositis, Guillain-Barré syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis (including exacerbation), hemolytic anaemia, pure red cell aplasia (PRCA), myelitis, vasculitis, hypoparathyroidism, myocarditis, sclerosing cholangitis, Solid organ transplant rejection, acute graft-versus-host-disease (GVHD), Elevated liver enzymes when KEYTRUDA® is given in combination with axitinib (ALT and AST). Infusion-related reactions (including hypersensitivity and anaphylaxis) occurred in patients receiving KEYTRUDA®. Increased mortality in patients with multiple myeloma when KEYTRUDA® is added to a thalidomide analogue and dexamethasone. | **Undesirable Effects:** Most common adverse reaction (reported in 10% of patients) when KEYTRUDA® was used as a single agent were arthralgia, back pain, cough, vitiligo, abdominal pain, pruritis, rash, hyponatremia; when KEYTRUDA® was used in combination with chemotherapy were fatigue, asthenia, diarrhea, neutropenia, rash, alopecia, arthralgia, mucosal inflammation, stomatitis, anemia, thrombocytopenia, vomiting and white blood cell count decreased, hypertension, decreased appetite, palmar-plantar erythrodysesthesia syndrome, nausea, dysphonia, constipation, pyrexia. The following adverse reactions have been identified during post-approval use of KEYTRUDA®: Musculoskeletal and connective tissue disorders: arthritis, Eye disorders: Vogt-Koyanagi-Harada syndrome, Immune system disorders: hemophagocytic lymphohistiocytosis, Nervous system disorders: optic neuritis. Please refer to the local full prescribing information of KEYTRUDA® for more information.

To report Adverse Events (AEs) related to our products, please contact :

Mode of reporting the adverse event	Details
PV Dedicated Fax	0124-4647339
PV Toll Free Number	18001032642
E-mail	dpoc_india@merck.com
Postal Address	International Pharmacovigilance Department, MSD Pharmaceuticals Pvt. Ltd., 6 th Floor, Vatika Towers-B, Sector-54, Gurgaon- 122002.

Adverse Event (AE): Per the International Conference on Harmonization (ICH), an adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this product.
PRIVACY CLAUSE: For recording of any kind of Adverse Event and/or Product Quality Complaint MSD in India will need certain personal information of the patient and/or reporter for official purpose and the patient and/or reporter of Adverse Event and/or Product Quality Complaint will be requested to provide the required Personal Information. For any other request other than Adverse Event Reporting and/or Product Quality Complaint Reporting, the information shall be shared basis MSD internal guidelines. Please be informed that MSD will save the information you share with us. The information will be handled strictly in accordance with MSD Privacy Standards. It may be shared globally within MSD group that handles adverse events, quality complaints and responds to medical inquiries. It will not be shared outside of MSD group and its affiliates except to companies acting on behalf of MSD or with government authorities or agencies. Please note that to fulfill legal requirements MSD might be sharing information concerning adverse events and other reportable events with medical/regulatory authorities. MSD in India and our partners will use the information to handle your question. Anonymized information will also be used for statistical and quality assurance purposes. In case you want to edit or delete Personal Health Information (PHI) already in possession of MSD in India you may request by writing to the below e-mail address pharmacovigilance.india@msd.com or FAX at +91-124-4647339. In case you would like to have any further details on Privacy you may visit MSD India website at www.msdingia.com
Before prescribing KEYTRUDA®, please read the full Prescribing Information.
For the use only of registered medical practitioners.

Alkem's range of own manufactured brand

^{Rx} **CETUXA**
Cetuximab 100 mg/20ml
Empower Hope

^{Rx} **ROMISET** 125mcg
250mcg
500mcg
Romiplostim
BOOST and SUSTAIN PLATELET COUNT

^{Rx} **ADVAMAB**TM 100mg
400mg
Bevacizumab Inj.
 **Add Precious Time**

^{Rx} **Denub**[®]
Denosumab
FOR BETTER LIFE

ALKEM LABORATORIES LTD.
ALKEM HOUSE, S. B. Road, Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Tel: +91-22-3982 9999 • www.alkemlabs.com

Wait is Over

"Significant Overall Survival outcome achieved at 10 Yrs."

(ASCO 2024 update)



BIOMab EGFR[®]
(Nimotuzumab Injection)

TARGET SUPERIOR OUTCOMES

In treatment of Locally advanced squamous cell carcinoma of Head & Neck

The 10-year Overall Survival was 22.5% versus **33.5%** (in the CRT and **NCRT arm** respectively (p=0.044)

Biomab plus Cisplatin RT gave **11 months longer** median Overall Survival benefit vs Cisplatin RT alone (p=0.04)

There was **"no statistically significant difference"** in late term adverse events after Biomab addition to Cisplatin RT

BIOMab EGFR[®]
(Nimotuzumab Injection)


TARGET SUPERIOR OUTCOMES

only
The **^** Anti-EGFR that has been proven to be
efficacious in LASCCHN along with Cisplatin RT*




Reference: Pathak VM, Moolcha V et al. Long-term results from a randomised phase III study of Nimotuzumab plus concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone in locally advanced squamous cell carcinoma of the head and neck: a randomised phase III study of biomab trial. <https://ascopubs.org/doi/10.1200/JCO.2024.42.17>. [suppl.] 186405F.

Storage/Preservation Information: For the use only at an Oncologist or a Hospital or a Laboratory. BIOMab EGFR (Nimotuzumab injection) Refer to complete prescribing information leaflet before opening the packet. Further information is available upon request. Composition: BIOMab EGFR 50 mg, vial contains: Nimotuzumab 50 mg (Nimotuzumab with 10% sucrose-based antiseptic), Sodium phosphate dibasic 18.5mg, Sodium phosphate monobasic 4.5mg, Sodium chloride 96.0mg, Polysorbate 80 2.0mg and Water for injection q.s. to 10ml, indications: Nimotuzumab is indicated for use in the treatment of advanced Squamous Cell Carcinoma of Head and Neck (HNSCC) along with concurrent chemotherapy and/or radiotherapy. Dosage and Administration: Nimotuzumab is administered as continuous intravenous (IV) infusion in weekly doses of 200mg for 4 weeks, in combination with a standard radiotherapy and/or chemotherapy for head and neck cancer. 200mg of the antibody is diluted in 250ml of sodium chloride and infused over 90 minutes. During infusion with neutral saline ensure that all practitioners are taken to avoid accidental contamination. In case of any leakage being seen in the solution it is due to accidental microbial contamination. In such case please discard the solution and prepare a fresh solution. Contraindications: None known. Warnings and Precautions: BIOMab EGFR should be used with caution in patients with known hypersensitivity to Nimotuzumab or to any of the known components of the formulation. Use in Pregnancy and Lactation: Human IgG1 is known to cross the placental barrier, but it is not known whether the antibody can cause fetal harm when administered to a pregnant woman, or any woman during breast-feeding or patients with local and systemic cancer, where Nimotuzumab was used concurrently with or without radiotherapy and/or chemotherapy, the commonly reported adverse events in the radiotherapy group were: fever, chills, myalgia, pruritus, urticaria/itch, headache, hypotension and hypoxia in blood pressure. The reported adverse events in the chemotherapy group were: mucositis, anemia, leucopenia, thrombocytopenia, vomiting and loose stools. Only rash and chills were stated by the investigator as causally related to Nimotuzumab. Anaphylactic skin reaction was the only serious adverse event (SAE) reported due to Nimotuzumab, others were due to the underlying malignant disease or as a result of treatment with concurrent chemotherapy or radiotherapy. In another clinical trial employing adequate contraception if the potential benefits outweigh the potential risk to the fetus, if the patient becomes pregnant while receiving this drug, she should be informed of the potential hazard to the fetus and/or the potential risk for loss of the pregnancy. Since human IgG1 is secreted in breast milk, the potential for absorption and harm to the infant after ingestion is unknown. No contraindication is made on the potential benefit versus risk of administering Nimotuzumab to nursing mothers. Undesirable Effects or Side Effects on advanced nasopharyngeal squamous carcinoma, the most commonly observed adverse reactions include: low fever, hypotension, nausea, dizziness and skin rash. Adverse reactions observed in clinical trials where Nimotuzumab was used along with radiotherapy for the treatment of advanced squamous cell carcinoma of head and neck cancer, were: fever, myalgia, nausea and vomiting, chills, hypotension, weakness, headache, pruritus and skin rash. Most of the skin reported during the study where Nimotuzumab was combined with radiotherapy were associated with radiation, adverse reaction and fatigue were the most commonly reported non-radiation associated AEs. Headache being not not exacerbated by the addition of Nimotuzumab to standard radiotherapy. Precaution: Available as single course of 4 vials and each Vial of 10ml (20.0 mg) of Nimotuzumab.



CINV prevention throughout
● **5 days** post-chemotherapy
with simplified regimen²

Single-dose, **Easy to Swallow tablets of Nykron** offers more convenience
in both acute & delayed phase of CINV^{1,2}



● 1-day **Nykron** is proven to be
more effective than 3-day APR^{4,5}

Lesser incidence of breakthrough
CINV with **NEPA** than APR⁵



● **NEPA** is comparatively **more economical** than Fosaprepitant³

CINV: Chemotherapy-induced nausea & vomiting; **NEPA:** Netupitant + Palonosetron; **APR:** Aprepitant; **NCCN:** National Comprehensive Cancer Network; **MASCC:** Multinational Association of Supportive Care in Cancer; **ESMO:** European Society for Medical Oncology.

References:

1. Lorusso V, et al. Management of chemotherapy-induced Nausea & Vomiting (CINV): a short review on the role of Netupitant-Palonosetron (NEPA). Core evidence. 2020;15:21
2. Lorusso V. Management of chemotherapy-induced nausea & vomiting by risk profile: role of netupitant/palonosetron. Ther Clin Risk Manag. 2016;12:917-925. Published 2016 Jun 7. doi :10.2147/TCRM.S89215
3. Data on file
4. J Clin Oncol 39, 2021 (suppl 15; abstr 12091)
5. Navari RM, et al. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea & vomiting: a pooled analysis. Future Oncol. 2021; 17(23):3027-3035.

Launching
SOON

World's ¹st and only
USFDA Approved¹
Immunotherapy in RM-NPC*

ZYTORVI™

toripalimab-tpzi injection
240mg/6mL (40mg/mL)

A Next-Generation Anti-PD-1²

For the use of registered medical practitioner, hospital and laboratory only.
Images appearing herein are for illustration purposes only.



Scan the QR code for ABPI



* RM-NPC- Recurrent Metastatic Nasopharyngeal Carcinoma,
1. Research C for DE and. FDA approves toripalimab-tpzi for nasopharyngeal carcinoma. FDA [Internet]. 2023 Oct 30; Available from: <https://www.fda.gov/drugs/resources-information-a-proved-drugs/fda-approves-toripalimab-tpzi-nasopharyngeal-carcinom> Accessed on 28/08/2024
2. Ravindranathan S, Wang X, et al. Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L1 status. J Immunother Cancer 2023;11(Suppl 1):A1-A1731.

TRANSFORMING

Head and Neck cancer
patient journey with

^{Rx}
Lupitux
Cetuximab 100 mg/ 20 ml Injection





In 1st line R/M SCCHN provide

Powerful* Start



In 1st Line R/M- SCCHN patients

Erbix[®] + CT has consistently shown high ORR irrespective of CPS in clinical studies.⁵⁻¹⁰

Erbix[®] + CT significantly provide symptomatic relief like pain and swallowing compared with CT alone.⁵

Sequencing is the key - 1L Erbix[®] + CT followed by 2L ICI has demonstrated up to 21.9 months of mOS⁶⁻¹¹

5. Vermorken JB, et al. N Engl J Med 2008;359:1116-1127; 6. Guo Y, et al. ASCO 2019 (Abstract No. 6018 - presentation); 7. Guigay J, et al. Lancet 2021; 8. Guigay J, et al. Ann Oncol 2015;26:1941-1947; 9. Bossi P, et al. Ann Oncol 2017;28:2820-2826; 10. Tahara M, et al. Ann Oncol 2018;29:1004-1009; 11. Chandrakanth M V, et al. F1000Research 2023



Date of Information: June 2019 Based on CCDS of Cetuximab V.16.0 dated 28th June 2018.
For further information refer to full prescribing information or write to:

Merck Specialities Pvt Ltd.,
Godrej One, 8th Floor, Pirojsha Nagar, Eastern Express Highway, Vikhroli (East) Mumbai - 400079
ERBITUX is a trademark of ImClone LLC, used under license by Merck KGaA and its affiliates[®].

*DISCLAIMER: This document / communication is for the use of Registered Medical Practitioners only. The data is for academic and educational purpose only. Certain data are based on data collected from scientific publications and on case studies and testimonials, which do not necessarily reflect the views, ideas and policies of Merck and Merck makes no representations of any kind about the accuracy or completeness of the same. It may refer to pharmaceutical products, diagnostic techniques, therapeutics or indications not yet registered or approved in a given country and it should be noted that, over time, currency and completeness of the data may change. For updated information, please contact the Company. Refer User Manual & Full Prescribing Information for more details. The data should not be used to diagnose, treat, cure or prevent any disease or condition without the professional advice of a Registered Medical Practitioner, and does not replace medical advice or a thorough medical examination. Registered Medical Practitioners should use their independent professional judgement in checking the symptoms, diagnosing & suggesting the appropriate line of treatment for patients. Merck is not in any way influencing, propagating or inducing anyone to buy or use Merck products. Merck accepts no liability for any loss, damage or compensation claims in connection with any act or omission by anyone based on information contained in or derived through use of this document / communication. Duplication of or copying any data requires prior permission of the copyright holder.

RLS is a leading player in developing, manufacturing and commercializing Biosimilars

- Has 23 biosimilars approved in India and deepest pipeline globally
- Launched 7 of the world's first biosimilars

DenosuRel[®]

Denosumab injection (120mg/1.7ml) for subcutaneous use

World's first Denosumab oncology biosimilar



ReliTrexed[®]

Pemetrexed disodium 100 mg, 500 mg injection

Efficacy with the safety edge!



Peg-ReliGrast[®]

Pegfilgrastim Injection 6 mg/0.6 ml

Best choice, when convenience matters



First Fixed I.V. Antiemetic Combination

Now available in **INDIA**

Akynzeo® I.V.

fosnetupitant /palonosetron



Unique single dose ready for dilution I.V. formulation

No reconstitution required

For the prevention of acute and delayed nausea and vomiting associated with highly emetogenic and moderately emetogenic chemotherapy*

Scan now
to access **ABPI**





OneCellTM
Diagnostics



OneCellDiagnostics
OncoIndxTM
NexGen Sequencing



OneCellDiagnostics
OncoIndxTMPrime
NexGen Sequencing



OneCellDiagnostics
OncoMonitorTM
Longitudinal Monitoring Test



OneCellDiagnostics
OncoRiskTM
Germline Test



OneCellDiagnostics
OncoDiscoverTM
Circulating Tumor Cell Test

Introducing

Roche's First Tumor Agnostic targeted therapy

 **ROZLYTREK™**
entrectinib 100mg | 200mg capsules

For the
Rare and
Relentless



Approved in India for the treatment of:

- ▶ **Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.**
- ▶ **Adult and pediatric patients 12 years of age and older with solid tumors that:**
 - ▶ Have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
 - ▶ Are metastatic or where surgical resection is likely to result in severe morbidity,
 - ▶ Have progressed following treatment or have no satisfactory alternative therapy.

Please use the QR code/click on the link for the latest Prescribing Information (PI)



https://bit.ly/Roche_Rozlytrek_PI

The image features the ThermoFisher Scientific logo centered on a white background. The logo consists of the word "ThermoFisher" in a bold, red, sans-serif font, with the "F" in "Fisher" having a distinctive shape. Below it, the word "SCIENTIFIC" is written in a smaller, black, all-caps, sans-serif font. The background is decorated with abstract, flowing red and white wavy patterns that create a sense of movement and depth.

ThermoFisher
SCIENTIFIC



**FRESENIUS
KABI**

caring for life

Relentless and Persistent endeavor
towards better Quality & patient Safety

Fresenius Kabi Presents a
comprehensive range of quality products

 **Nanoxel**[®]
Paclitaxel Nanoparticle
Nano Edge Paclitaxel

 **Intaxel**[®]
Paclitaxel

 **Daxotel**[™]
Docetaxel
The Superior Choice

 **Irinotel**[®]
Irinotecan
A Step Ahead

 **Oxitan**[™]
Oxaliplatin
The Platinum Edge

 **VINELBINE**[®]
Vinorelbine

CLADRIM[™]
Cladribine 10 mg Injection

 **THALIX**[®]
Thalidomide Capsules USP



Fresenius Kabi India Pvt. Ltd.

A-3, MIDC, Ranjangaon Ganpati, Tal. - Shirur, Dist. - Pune - 412220 Maharashtra, India. Consumer Care No.- 09158898288
Website: www.fresenius-kabi.com E-mail id: fkpl@fresenius-kabi.com CIN : U24231PN1995PTC014017

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.



Thoughtful innovations for Powerful Outcome

The Differentiative Lenvatinib

LENSHIL[®]

Lenvatinib Capsules 12mg/18mg

The Dispersible Capecitabine

Capebel DT

Capecitabine 500 mg/1000 mg Dispersible Tablets



Management of Advanced Prostate Cancer

Leupr♂t 22.5 mg

Leuprolide Acetate for Injection 22.5 mg (Depot)

Management of mCRPC & nmCSPC

Shilrazone 250 MG 500 MG
ABIRATERONE ACETATE TABLETS

The Conventional Capecitabine

SHILCAP[®]

Capecitabine 500mg Tablet

AZISHIL[®]

Azacitidine for Injection 100 mg

*State-of-the-art manufacturing facilities
with international accreditations*



Organized by



Supported by



7th Annual International Review in Head & Neck Cancers

28th - 29th September, 2024

Venue: Royal Palace, NSCI, Worli, Mumbai

2023

2024

Conference managed by:

riverroute[®]

Conference Secretariat

Mr. Rohan Kulkarni

Mobile No: +91 98206 20418

E-mail: rrcg.rohank@gmail.com

River Route Creative Group

Mumbai

Click on the link below for registration
<https://riverroute.in/arhnc2024>

Managed by

riverroute[®]